renal

Recent Articles

RELATED ARTICLES

  1. Freitane, Kintor’s fastest-progressing key product and as the world's first AR antagonist to have entered Phase III clinical trial for male androgenetic alopecia treatment, carried high hopes from investors but ended up being declared a failure.
    Kintor shares plunge after hair-loss drug flops in clinical trials
    9939.HK
  2. AstraZeneca pays hefty price for Chinese weight-loss drug
    AZN.US
  3. With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs
    GRCL.US
  4. Akeso marks profit milestone with swift rights issue
    9926.HK
  5. HBM gets health boost from drug licensing deals
    2142.HK
  6. Adlai Nortye dives in Nasdaq debut, as key product faces hurdles
    ANL.US
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva